| 中文名 | Ubrogepant |
|---|---|
| 英文名 | (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide |
| 中文别名 |
乌布吉汁
乌布吉泮相关杂质 (S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2'-氧代-1',2',5,7-四氢螺[环戊二烯并[b]吡啶-6,3'-吡咯并[2,3-b]吡啶]-3-甲酰胺 |
| 英文别名 |
MK-1602 Ubrogant
Ubrogant API Ubrogant, 10 mM in DMSO Spiro(6H-cyclopenta(b)pyridine-6,3'-(3H)pyrrolo(2,3-b)pyridine)-3-carboxamide,1',2',5,7-tetrahydro-N-((3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl)-2'-oxo-,(3'S) Ubrogant Ubrogant D5 Ubuzhipan MK1602,MK 1602,Ubrogant,inhibit,Inhibitor,Calcitonin gene-related ptide rector,CP Rector (S)-N-((3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-cboxamide MK-1602 (3'S)-N-((3S,5S,6R)-6-Methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro(cyclopenta(b)pyridine-6,3'-pyrrolo(2,3-b)pyridine)-3-carboxamide Ubrogepant [USAN] Spiro[6H-cyclopenta[b]pyridine-6,3'-[3H]pyrrolo[2,3-b]pyridine]-3-cboxamide, 1',2',5,7-tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2'-oxo-, (3'S) |
| 描述 | Ubrogepant (MK-1602) 是一种新型口服降钙素基因相关肽受体 (CGRP) 拮抗剂,正在开发治疗急性偏头痛。 |
|---|---|
| 相关类别 | |
| 靶点 |
MK-1602[1] |
| 参考文献 |
| 密度 | 1.45±0.1 g/cm3(Predicted) |
|---|---|
| 沸点 | 729.4±60.0 °C(Predicted) |
| 分子式 | C29H26F3N5O3 |
| 分子量 | 549.54400 |
| 精确质量 | 549.19900 |
| PSA | 111.27000 |
| LogP | 4.12840 |
| 储存条件 | -20°C, 密封 |